Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Evaluation of the efficacy of different large language models in solving clinical problems of early gastric cancer].

Zhonghua yi xue za zhi·2026
Same author

Study of memory-dependent dynamics of a predator-prey model with hyperbolic mortality.

Scientific reports·2026
Same author

Correlates of HIV-1 control after combination immunotherapy.

Nature·2025
Same author

Fly Density Does Not Limit <i>Ceratocystis fimbriata</i> Transmission to Sweetpotato by <i>Drosophila hydei</i>, Revealed Through Molecular Diagnostics.

Phytopathology·2025
Same author

Predictors of vision-related quality of life in patients treated for filamentous fungal keratitis.

The ocular surface·2025
Same author

How honeybees perceive and traverse apertures.

The Journal of experimental biology·2025

Related Experiment Video

Updated: Jun 29, 2026

Establishing a Porcine Ex Vivo Cornea Model for Studying Drug Treatments against Bacterial Keratitis
09:22

Establishing a Porcine Ex Vivo Cornea Model for Studying Drug Treatments against Bacterial Keratitis

Published on: May 12, 2020

Corticosteroids for bacterial corneal ulcers.

M Srinivasan1, P Lalitha, R Mahalakshmi

  • 1Aravind Eye Care System, Madurai, India.

The British Journal of Ophthalmology
|October 3, 2008
PubMed
Summary
This summary is machine-generated.

Adjunctive topical corticosteroids in bacterial keratitis did not significantly improve visual acuity or reduce scar size. While steroids delayed healing, a larger clinical trial is needed to fully assess their impact on vision outcomes.

More Related Videos

Evaluating Therapeutic and Chemical Toxicity Using Organ-Cultured Porcine Corneas and Epithelial Wound Healing
03:57

Evaluating Therapeutic and Chemical Toxicity Using Organ-Cultured Porcine Corneas and Epithelial Wound Healing

Published on: January 10, 2025

Related Experiment Videos

Last Updated: Jun 29, 2026

Establishing a Porcine Ex Vivo Cornea Model for Studying Drug Treatments against Bacterial Keratitis
09:22

Establishing a Porcine Ex Vivo Cornea Model for Studying Drug Treatments against Bacterial Keratitis

Published on: May 12, 2020

Evaluating Therapeutic and Chemical Toxicity Using Organ-Cultured Porcine Corneas and Epithelial Wound Healing
03:57

Evaluating Therapeutic and Chemical Toxicity Using Organ-Cultured Porcine Corneas and Epithelial Wound Healing

Published on: January 10, 2025

Area of Science:

  • Ophthalmology
  • Infectious Diseases
  • Clinical Trials

Background:

  • Bacterial keratitis is a serious eye infection that can lead to vision loss.
  • The role of adjunctive topical corticosteroids in managing bacterial keratitis remains debated.
  • Optimizing treatment strategies is crucial for improving patient outcomes and preventing complications.

Purpose of the Study:

  • To assess the efficacy of adjunctive topical corticosteroids in bacterial keratitis.
  • To determine the feasibility and sample size for a larger trial if no significant difference is found.

Main Methods:

  • A single-center, double-masked randomized clinical trial was conducted.
  • 42 patients with culture-confirmed bacterial keratitis received topical moxifloxacin plus either topical prednisolone phosphate or placebo.
  • Primary outcome was best spectacle-corrected visual acuity (BSCVA) at 3 months; secondary outcomes included healing time, scar size, and adverse events.

Main Results:

  • Topical corticosteroids significantly delayed re-epithelialization compared to placebo (HR 0.47, 95% CI 0.23-0.94).
  • No significant differences were observed in BSCVA or infiltrate/scar size at 3 weeks or 3 months between groups.
  • A larger trial would require 360 cases to detect a two-line difference in visual acuity with 80% power.

Conclusions:

  • Adjunctive topical corticosteroids in bacterial keratitis did not lead to significant improvements in visual acuity or scar size.
  • Despite a statistically significant delay in re-epithelialization, corticosteroids did not increase adverse events.
  • A larger, feasible clinical trial is warranted to definitively assess the effect of steroids on visual acuity in bacterial keratitis.